Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on June 26, 2017. The report covers events occurring on that date regarding intellectual property developments.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a specific corporate event rather than financial performance.
Material Changes
The material change reported is the allowance of patent claims by regulatory bodies:
- U.S. Patent and Trademark Office: Allowed claims for Patent Application 13/959739.
- European Patent Office: Allowed claims for Patent Application EP10184598.0.
- Subject Matter: Both applications are entitled "Nucleophosmin Protein (NPM) Mutants, Corresponding Gene Sequences and Uses Thereof."
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future outlook, or specific risk factors beyond the context of the patent allowance. The event is reported under Item 8.01 (Other Events).
Investor Verification Checklist
- Verify the exact scope of the allowed claims in Patent Application 13/959739 and EP10184598.0.
- Confirm the commercial potential of the Nucleophosmin Protein (NPM) mutants covered by these patents.
- Review the attached press release (Exhibit 99.1) for additional details on the patent strategy.
- Note the discrepancy between the requested company name (Cardiff Oncology) and the filing registrant (Trovagene).